Angiodynamics released FY2025 Q3 earnings on April 2 Pre-Market (EST), actual revenue 72 M USD (forecast 70.3 M USD), actual EPS -0.11 USD (forecast -0.265 USD)

Brief Summary

Angiodynamics reported 2025 Q3 revenue of $72 million, exceeding the expected $70.3 million, with an EPS of -$0.11, better than the expected -$0.265.

Impact of The News

The financial briefing on Angiodynamics’ performance indicates a mixed outlook:

1. Revenue Performance:

• The actual revenue of $72 million surpassed the market expectation of $70.3 million, representing a 9.2% increase compared to previous period forecasts Benzinga+ 2. Despite a year-over-year decrease of 4% in revenue from $75 million in the previous year, the company managed to exceed current quarter expectations Benzinga+ 2.

2. Earnings Per Share (EPS):

• The EPS of -$0.11 was better than the anticipated -$0.265, indicating a narrower loss than the market had feared Benzinga.

3. Business Segment Performance:

• The Med Tech segment saw a significant increase, with net sales growing by 22.2% to $31.3 million. Product-specific performance was strong: Auryon revenues grew by 17.3%, AngioVac by 23.1%, AlphaVac by 161.4%, and NanoKnife disposables by 16.2% Benzinga.

4. Market Position and Outlook:

• In terms of industry benchmarks, such financial results appear competitive given the Med Tech sector’s performance. However, the company continues to operate at a loss, which might concern investors looking for profitability Reuters+ 2.
• The company has guided a fiscal year 2025 sales outlook of $285 million to $288 million with a gross margin of 53%-54%, which suggests an optimistic revenue trajectory and profitability improvement Reuters+ 2.

By analyzing these aspects, Angiodynamics shows resilience through revenue growth in its Med Tech division, despite facing ongoing profitability challenges. The improved performance in expected revenue and narrower-than-expected losses may bolster investor confidence in the company’s strategic direction and operational execution.